Clinical trials: Major Depressive Disorder
Major Depressive Disorder
Brain Imaging Techniques That Predict Antidepressant Responsiveness
Do functional brain changes occur during Venlafaxine ER (extended release) versus Fluoxetine treatment and do changes in selective structures, such as the amygdala, predict treatment response?
- Trial name
- WyethKolden (NCT00909155)
- Testing
- Venlafaxine ERT, Fluoxetine
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Depression, Alcoholism
Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism
We will study patients with a current major depressive episode, comorbid alcoholism and a history of a past suicide attempt. All subjects with alcohol dependence will be evaluated for risk of alcohol withdrawal prior to…
- Conditions
- Depression, Alcoholism, Suicidal Behavior
- Trial name
- NCT00449007
- Testing
- fluoxetine, bupropion
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- New York State Psychiatric Institute
Depressive Disorder, Major
Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.
- Trial name
- NCT01163266
- Testing
- Vortioxetine
- Where
- 39 sites in United States
- Volunteers
- 462 people
- Sponsor
- Takeda
Major Depressive Disorder
Empower: tDCS for Major Depressive Disorder at Home
A two-center trial to investigate whether or not active stimulation with the Flow FL-100 tDCS device is superior to sham stimulation for the treatment of major depressive disorder when used at home.
- Trial name
- NCT05202119
- Testing
- Transcranial direct current stimulation
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 174 people
- Sponsor
- Flow Neuroscience AB
Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an…
- Trial name
- NCT01111565
- Testing
- Escitalopram, Aripiprazole
- Where
- 53 sites in United States, Canada and 9 more
- Volunteers
- 137 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
Therapist-Guided Smartphone-Delivered CBT for MDD
We are testing a smartphone app that provides therapy for depression. Participants will also receive short weekly virtual appointments with a therapist.
- Trial name
- NCT05386329
- Testing
- Mindset: Therapist-guided smartphone-delivered CBT
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Vilazodone for Treatment of Geriatric Depression
The purpose of this study is to examine the effects of vilazodone for the treatment of depression in older adults.
- Trial name
- NCT01608295
- Testing
- Vilazodone; Viibryd, Paroxetine; Paxil
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of California, Los Angeles
Depression, Unipolar Depression
Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression
This trial aims to assess the efficacy and tolerability of Magnetic Seizure Therapy (MST) as an alternative to electroconvulsive therapy (ECT) for depression.
- Conditions
- Depression, Unipolar Depression, Treatment Resistant Depression
- Trial name
- CREST-MST (NCT03191058)
- Testing
- Magnetic Seizure Therapy, Electroconvulsive Therapy
- Where
- 3 sites in United States, Canada
- Volunteers
- 239 people
- Sponsor
- University of Texas Southwestern Medical Center
Major Depressive Disorder
Study Comparing the Efficacy of Venlafaxine XR Vs. SSRIs and Conventional Antidepressants in Depressed Patients
This study is an open-label, randomized, multi-center study conducted in a typical psychiatric outpatient practice in China. This study is intended to collect data on the efficacy and safety of venlafaxine XR (Efexor XR®) versus…
- Trial name
- NCT00474708
- Testing
- Effexor, SSRI
- Where
- 26 sites in China
- Volunteers
- 1,151 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depression
Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression
This study will evaluate the effectiveness of adding motivational interviewing to antidepressant treatment for major depressive disorder in Hispanic adults.
- Trial name
- NCT00564278
- Testing
- Standard antidepressant therapy (SADT), Motivational antidepressant therapy (MADT)
- Where
- United States
- Volunteers
- 217 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder, Alcohol Abuse
Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism
This is a study about treatment for people who suffer from both major depression and alcohol abuse or dependence. The study will examine whether the addition of acamprosate to escitalopram and behavioral interventions will…
- Conditions
- Major Depressive Disorder, Alcohol Abuse, Alcohol Dependence
- Trial name
- NCT00452543
- Testing
- acamprosate, escitalopram, Medical management
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
A Study of CX157 (TriRima) for the Treatment of Depression
The purpose of this study is to examine the efficacy of CX157 60 mg administered three times a day (180 mg daily dose) as compared to placebo in subjects with Major Depressive Disorder (MDD).
- Trial name
- CX157-200 (NCT00739908)
- Testing
- CX157 (TriRima)
- Where
- 14 sites in United States
- Volunteers
- 285 people
- Sponsor
- CeNeRx BioPharma Inc.
Major Depressive Disorder, Alcohol Use Disorder
Treatment of Young Adults With Comorbid AUD/MDD: A Pilot Medication Trial
Recent reports have shown that alcohol misuse is a particularly serious problem among the 18 to 25 year old age group. Previous medication trials with SSRI antidepressants among young adults with co-occurring depressive…
- Trial name
- YAAD-P (NCT02646449)
- Testing
- Mirtazapine
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Depressive Disorder, Major
Memantine to Reduce Neurocognitive Deficits Following Unilateral ECT for the Treatment of a Major Depression
The purpose of this study is to determine whether taking the medication memantine reduces impairment of memory and attention associated with electroconvulsive therapy.
- Trial name
- NCT00186498
- Testing
- memantine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Stanford University
Depressive Disorder, Major
Study to Assess Clinical Response of Duloxetine in Patients Hospitalized for Severe Depression
Study to assess efficacy of Duloxetine 120 mg and Duloxetine 60 mg in patients hospitalized for severe depression after 4 weeks of treatment. To evaluate the rescue option in non-responding patients.
- Trial name
- NCT02229825
- Testing
- Duloxetine
- Volunteers
- 339 people
- Sponsor
- Boehringer Ingelheim
Major Depressive Disorder
A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy of two fixed doses of vortioxetine (Lu AA21004; 10 or 20 mg/day) after 8 weeks of treatment in patients with major depressive disorder (MDD) in Japan.
- Trial name
- NCT02389816
- Testing
- Vortioxetine
- Where
- 47 sites in Japan
- Volunteers
- 493 people
- Sponsor
- Takeda
Major Depressive Disorder
SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder
To evaluate the efficacy of SPD489 for the treatment of executive function impairments (EFI) when used as an adjunct to stable, standard therapy in the setting of partial or full remission from recurrent Major Depressive Disorder…
- Trial name
- NCT00985725
- Testing
- SPD489 (Lisdexamfetamine dimesylate)
- Where
- 33 sites in United States
- Volunteers
- 143 people
- Sponsor
- Shire
Depressive Disorder, Major
Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
This is a multicenter study to assess the health and well-being in subjects who are outpatients with major depressive disorder that take desvenlafaxine succinate sustained release (DVS SR) or placebo for 12 weeks.
- Trial name
- NCT00824291
- Testing
- desvenlafaxine succinate sustained release, Genotyping
- Volunteers
- 437 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders…
- Trial name
- NCT05061706
- Testing
- Lumateperone
- Where
- 50 sites in United States, Argentina and 5 more
- Volunteers
- 480 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Depression, Major Depressive Disorder
eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk
This pilot randomized controlled trial seeks: (1) to determine the preliminary efficacy of our modernized collaborative care intervention for depression in improving the diabetes risk markers of hemoglobin A1c and insulin…
- Conditions
- Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms
- Trial name
- NCT04437485
- Testing
- Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Indiana University